Objective: Adiponectin is an adipokine produced by adipose tissue. The present studies examined the in vitro release of adiponectin by human omental adipose tissue explants as well as the mRNA content of freshly isolated non-fat cells and adipocytes plus cultured preadipocytes and adipocytes derived from omental fat. Results: The release of adiponectin was reduced while that of interleukin-8 (IL-8) was enhanced in tissue explants from morbidly obese women. The release of adiponectin was also reduced by one-third in explants from morbidly obese diabetic women while that of IL-8 was unaffected by diabetes. The release of adiponectin was enhanced by insulin and by inhibition of endogenous tumor necrosis factor (TNFa) using etancercept. Adiponectin was released in appreciable amounts by the undigested matrix obtained by collagenase digestion of adipose tissue. The release of adiponectin by non-fat cells (matrix þ SV cells) was comparable to that by the adipocytes derived from the same amount of tissue while the adiponectin mRNA content of the pooled matrix and SV cell fractions was 40% of that in intact tissue. The adiponectin mRNA content was 48-fold greater in isolated adipocytes than in non-fat cells derived from adipose tissue. In contrast, the amount of adiponectin mRNA in vitro differentiated omental adipocytes was 1 Â l0 6 -fold greater than that in cultured preadipocytes while that of leptin was 3 Â 10 4 -fold greater. Conclusion: Adiponectin mRNA is present in the non-fat cells of freshly isolated adipose tissue and release by the non-fat cells derived from a gram of adipose tissue is comparable to that by adipocytes isolated from the same amount of tissue. While leptin is only released by mature adipocytes, adiponectin is released by both the non-fat cells and the fat cells derived from human omental adipose tissue.
Introduction
Adiponectin was discovered by Scherer et al. 1 in 1995 as a protein found in differentiated adipocytes, but not in preadipocytes, and also by Hu et al. 2 and Maeda et al. 3 The importance of this protein was not recognized until 1999 when Arita et al. 4 reported that the circulating level of adiponectin is decreased in obese humans. Subsequently, it was found that plasma levels of adiponectin are also reduced in type 2 diabetes. 5, 6 To date, adiponectin is the only known hormone released by adipose tissue whose circulating levels are reduced by obesity and/or diabetes. It is now thought that adiponectin has anti-diabetic, anti-atherogenic as well as anti-inflammatory properties and is a biomarker of the metabolic syndrome. 7, 8 Adiponectin was originally described as an adipocytespecific protein. [1] [2] [3] However, more recently adiponectin mRNA and secretion have been demonstrated in boneforming cells, 9,10 cardiomyocytes, 11 skeletal muscle, 12, 13 human liver, 14 human placental syncytiotrophoblasts 15 and human fetal tissues of mesodermic and ectodermal origin. 16 It is unclear whether tissues other than adipose tissue contribute to circulating levels of adiponectin that are some 40-fold higher than those of leptin in obese subjects. It is equally uncertain whether the non-fat cells of human adipose tissue contribute to adipose tissue release of adiponectin. Furthermore, it is not known how the expansion of adipose tissue that is seen in obesity results in higher release of leptin and lower release of adiponectin. Visceral adiposity correlates with insulin resistance. 17, 18 However, obesity causes enhanced accumulation of fat in all depots. But, there is a sex-linked effect in that men have relatively more visceral adipose tissue 'beer belly fat' than do women. 17 Because of the importance of visceral adipose tissue, this report focuses on in vitro studies using omental adipose tissue. However, we did not see any difference in adiponectin release between explants of subcutaneous as compared to omental adipose tissue. 19 Similar results have been reported with regard to adiponectin mRNA in subcutaneous versus omental adipose tissue of lean, obese and morbidly obese women. 20 However, two reports found lower levels of adiponectin mRNA in visceral omental adipose tissue as compared to subcutaneous adipose tissue; 21,22 while
Motoshima et al. 23 found a higher release of adiponectin by adipocytes isolated from omental as compared to those isolated from subcutaneous adipose tissue. Present studies were designed to compare the adiponectin release in vitro as well as the mRNA content of non-fat cells as compared to fat cells (adipocytes) of omental adipose tissue from obese women. The role of insulin and TNFa in the regulation of adiponectin release by omental adipose tissue extracts was also examined in these studies.
Materials and methods
Omental adipose tissue was obtained from women undergoing either laparoscopic adjustable gastric banding surgery or laparoscopic gastric bypass with Roux-en-y gastroenterostomy surgery for the treatment of morbid obesity as well as some women undergoing abdominoplasty. Approximately 40% of patients were age 40 or less, 40% were ages 40-49 and 20% were over the age of 50. The mean age of the controls was 37 and of the diabetics 42. Each experimental replication involved tissue from a separate individual. Fasting blood glucose values exceeding 125 mg dl À1 defined the 7 morbidly obese type 2 diabetic patients whose mean fasting blood glucose was 180 despite the fact that all were on diabetes medications (1 was taking only insulin, 2 insulin plus an oral agent, 3 were taking one oral agent and 1 was taking two oral agents). It should be noted that in a larger study of 58 type 2 morbidly obese diabetic women (body mass index (BMI) above 36 and age over 18), there was no correlation between age and fasting blood glucose (Pearson's correlation coefficient of r ¼ À0.07 and P ¼ 0.65). In 58 morbidly obese nondiabetic women, there was only a small and non-significant correlation between age and blood glucose (r ¼ 0.20 and P ¼ 0.12). In the same large group of 126 morbidly obese women, there was in fact a negative correlation between age and waist circumference (r ¼ À0.26 and P ¼ 0.05 in nondiabetic and r ¼ À0.27 and P ¼ 0.03 in diabetic women). The study had the approval of the local Institutional Review Board (IRB) and all patients involved gave their informed written consent. The omental adipose tissue was transported to the laboratory within 5-15 min of its removal from the donor. The handling of tissue and cells was done under aseptic conditions. The tissue was cut with scissors into small pieces (5-10 mg). All the studies utilized explants of adipose tissue that had been incubated in buffer plus albumin (3 ml g À1 of tissue) for approximately 1 min to reduce contamination of the tissue with blood cells and soluble factors. At the conclusion of this incubation, the tissue explants were centrifuged for 15 s at 400 g in order to remove blood cells and pieces of tissue containing insufficient adipocytes to float. The cut pieces of tissue were then incubated for an indicated time in suspension culture under aseptic conditions in buffer containing 17.5 mM glucose and with air as the gas phase. Adipocytes were prepared by incubating 0.5 g of cut adipose tissue per ml of incubation medium containing 0.6 mg ml À1 of bacterial collagenase in a rotary water bath shaker (100 r.p.m.) for 2 h. The collagenase digest was then separated from undigested tissue matrix by filtration through 200 mm mesh fabric. Five milliliters of medium was then added back to the digestion tubes and used to wash the undigested matrix on the filter mesh. This wash solution was combined with the collagenase digest and stromovascular (SV)-cell fraction separated from adipocytes and medium by centrifugation in 15 ml tubes for 1 min at 400 g. The SV cells are defined as those cells isolated by collagenase digestion that do not float. The SV cells and adipocytes were each suspended in 5 ml of fresh buffer and centrifuged for 10 s at 400 g. This medium was removed. The undigested tissue matrix on the nylon mesh, the SV cells and the adipocytes were incubated in a volume of 5 ml for the indicated period. The serum-free buffer for incubation of adipose tissue and adipocytes was as previously described. 24 The pH of the buffer was adjusted to 7.4 and then filtered through a 0.2 mm filter. Interleukin-8 (IL-8), leptin and adiponectin release to the medium were determined using an ELISA assay with Duoset reagents from R&D Systems of Minneapolis, MN. Lactate release was determined using lactate dehydrogenase. Human omental preadipocytes were isolated from the SV cell fraction obtained after collagenase digestion of human omental adipose tissue as previously described. 25 Isolation of total RNA from preadipocytes and differentiated adipocytes was performed using an RNAeasy Mini Kit according to the manufacturer's protocol (Qiagen Inc., Valencia, CA, USA). For studies involving mRNA isolation from omental adipose tissue approximately 0.5 g of tissue or the fractions derived from 1 g of tissue the matrix (SV cells or adipocytes) were homogenized using a polytron homogenizer with 5 ml of a monophasic solution of phenol and guanidine isothiocyanate (TRIzol reagent from Invitrogen of Carlsbad, CA, USA). The extracts were then spun at 12 000 g for 10 min at 2-81C and the fat layer on top of the extract removed using a Pasteur pipette. Total RNA was obtained from the cleared homogenate by the procedure of Chomczynski and Sacchi. 27 The cDNA was prepared using the Transcriptor First Strand cDNA synthesis Kit from Roche Diagnostics. The quantification of mRNA was accomplished using the Roche Lightcycler 480 Real-time RT-PCR system and the Universal Probe Library of short hydrolysis locked nucleic acid (LNA) probes in combination with the primers suggested by their webbased assay design center (www.universalprobelibrary.com). Integrated DNA Technologies of Coralville, IA, synthesized the primers. Approximately 70 ng per tube of total mRNA was used for each assay. The data are obtained as crossing point values (Cp) obtained by the second derivative maximum procedure. Samples with higher copy number of cDNA have lower Cp values, while those with lower copy numbers have the reverse. Relative quantification of the data as well as the ratio of mRNA in fat cells to non-fat cells and of preadipocyte to adipocytes was based on the comparative Cp method that eliminates the need for standard curves. The arithmetic formula to calculate ratios from DCp is 2
ÀDCp . This procedure is identical to the comparative C T procedure described in the ABI PRISM 7700 Sequence Detection System user Bulletin #2 for quantitative RT-PCR except that Cp is used, since Roche uses the crossing point procedure instead of crossing threshold to calculate cycles required for detection of mRNA. The calculation of ratios assumes that the number of target molecules doubles with every PCR cycle. It is not possible to directly compare the DCp values for one gene with another because of the relative efficiencies of the particular primers and probes used for each gene are different.
Results
The release of adiponectin was reduced by 67%, while that of IL-8 was enhanced by 228% in explants of adipose tissue incubated for 48 h from women with a BMI of 45 as compared to women with a BMI of 32 ( Figure 1a) . The release of adiponectin was reduced by 34% in omental adipose tissue explants from obese diabetic women as compared to that by tissue from morbidly obese women with similar BMI values while that of IL-8 was unaffected (Figure 1b) . The enhanced release of inflammatory mediators such as IL-8 by adipose tissue from morbidly obese women is in agreement with prior results. 28 Another inflammatory mediator is TNFa whose release by human adipose tissue explants over a 4 h incubation was negatively associated (Pearson's r ¼ À0.60) with the release of adiponectin. 29 Kern et al. 30 found a similar negative correlation between plasma adiponectin and adipose tissue TNFa mRNA as well as adiponectin mRNA content in adipose tissue versus TNFa secretion over a 2 h incubation of adipose Figure 2 show that inhibition of endogenous TNFa release over a 48 h incubation of omental adipose tissue explants with etanercept (Enbrel) enhanced adiponectin release by 30%. A similar increase in adiponectin release over 48 h was seen in the presence of insulin and the effect was not additive to that of etanercept ( Figure 2 ). There was appreciable release of adiponectin, but not of leptin, by the matrix and SV fractions obtained by collagenase digestion of adipose tissue over 48 h (Figure 3) . The release of adiponectin by adipocytes derived from a gram of tissue was only slightly higher than that by the matrix fraction derived from the same amount of tissue (Figure 3) . The release of lactate is included for comparison and indicates that while the SV-cell fraction derived from a gram of tissue released as much lactate as the adipocyte fraction but only 6% as much adiponectin as the adipocytes. In contrast, adiponectin release by the matrix fraction was 86% of that by the adipocytes while lactate formation was 5-fold greater than that by adipocytes (Figure 3) .
If the release of adiponectin by the adipose tissue cellular matrix fraction represented synthesis in the cells in the cellular matrix, there should be mRNA present in the matrix þ SV cell fractions. The adiponectin mRNA content in the pooled matrix þ SV fractions was 25% while that of leptin was 12% of that in cut pieces of omental adipose tissue (Figure 4) . The adiponectin and leptin mRNA content of freshly isolated adipocytes was 20-and 6-fold greater than that of adipose tissue mRNA. However, there was virtually no detectable adiponectin mRNA (o0.03%) in preadipocytes derived from the SV cell fraction after primary culture for 7 days, while that of leptin in preadipocytes was 1% of that in omental adipose tissue (Figure 4 ). In contrast, the amount of adiponectin and leptin mRNA in differentiated adipocytes was 208-and 39-fold greater respectively than that of adipose tissue.
The ratio of adiponectin, leptin and perilipin mRNA contents in omental adipocytes obtained by differentiation of preadipocytes as compared to the preadipocytes was far greater than that of adipocytes as compared to the pooled matrix þ SV cell fractions (Table 1) . Perilipin was used as a control since it is a protein involved in lipolysis that is localized in adipocytes. PPARg 1-2 (the probes do not (matrix þ SV fractions), adipocytes, preadipocytes and in vitro differentiated adipocytes as compared to that in omental adipose tissue. The data for mRNA content are expressed as the ratio of that in the four fractions to that in omental adipose tissue explants expressed on a log 2 scale that is based on the DCp values for six experiments using isolated omental adipose tissue, adipocytes and the non-fat cells (pooled-matrix þ SV fractions), four experiments using preadipocytes obtained from omental adipose tissue and three experiments using in vitro differentiated adipocytes.
Adiponectin release by adipose tissue JN Fain et al distinguish between the isoforms) was found to be enriched in adipocytes, but not to nearly the same extent as perilipin, leptin or adiponectin. Interestingly, PPARg was found to a greater extent in freshly isolated adipocytes than in adipocytes differentiated in vitro ( Table 1 ). The SV cell fraction is those cells released by collagenase digestion that do not float while the matrix is those cells remaining in adipose tissue after collagenase digestion. Preadipocytes are essentially obtained by culturing the SV cell fraction for a week in the presence of insulin and dexamethasone plus serum and other factors. The question was whether adiponectin is enriched in the SV fraction as compared to the adipose tissue matrix was examined in the studies shown in Table 2 . Just the reverse was seen in that adiponectin mRNA content in the SV fraction was 27% of that in the matrix fraction. Complement factor C3 mRNA was included since it is one mRNA that is present to the same extent in both fractions, while leptin, perilipin and PPARg1-3 mRNAs were present to a significantly lesser extent in SV than in the matrix cell fraction.
Discussion
The present results confirm the finding originally noted in murine 3T3 cells 1,2 that adiponectin mRNA is not expressed in preadipocytes and extend these findings to human omental preadipocytes. We also found some adiponectin mRNA in freshly isolated human adipose tissue SV cells; but the amount of adiponectin mRNA was 4-fold greater in the adipose tissue matrix than in SV cells. These data suggest that the release over 48 h of adiponectin by the adipose tissue matrix obtained after a 2 h digestion of tissue with collagenase represents synthesis by cells in the matrix. The matrix includes endothelial and smooth muscle cells associated with the blood vessels along with fibroblasts and other cells comprising undigested connective tissue. One problem is that mRNA levels are not always reflected in protein levels. This was the case with regard to leptin whose mRNA was present in the matrix þ SV fractions of omental adipose tissue at levels 12% that in tissue but there was no release of leptin. While the data suggest that as much as half of adiponectin release could be by the non-fat cells of adipose tissue, this conclusion is based on fractions obtained by collagenase digestion. Possibly this procedure has more deleterious effects on adiponectin release by adipocytes than by the tissue-matrix fraction.
In short-term studies with human omental adipose tissue, the release of bound adiponectin is a problem because of the relatively high-circulating concentrations of adiponectin. However, it was possible to see net release, after correcting for the change in tissue adiponectin, over 2 h of approximately 5 pmol g À1 of adiponectin by omental adipose tissue. 28 Approximately, the same rate of release was seen by cut pieces of adipose tissue that did not contain enough lipid to float. 28 The view that the expression of adiponectin mRNA is restricted to mature adipocytes is clearly untenable in view of the present findings and the recent reports that adiponectin is synthesized and secreted by human osteoblasts, 10 human cardiomyocytes, 11 murine skeletal muscle, 12 human skeletal muscle and placenta, 13 human liver biopsies, 14 human placental synctiotrophoblasts, 15 as well as human fetal tissues of both mesodermal and ectodermal origin. 16 The present data using omental adipose tissue explants confirm the prior reports by Matsuzawa's laboratory that adiponectin release is reduced by obesity 4 as well as diabetes. 5, 6 It is still unclear exactly why leptin release is enhanced, while that of adiponectin is reduced in obesity. 7, 8 The negative correlation between IL-8 release and that of adiponectin by adipose tissue suggests that the obese state is associated with enhanced release of inflammatory cytokines in adipose tissue. A negative relationship has also been reported in vivo between plasma adiponectin and cytokines. 31 The values are the means of 8 experiments using fractions derived from omental adipose tissue from as many women. The DCp values are the means7s.e.m. of the paired differences for each individual and the P values are based on the paired differences. The ratio of each mRNA in the SV fraction to that in the matrix fraction was calculated from the DCp values (2
ÀDCp
). 35 found that etanercept alone had no effect on the release of IL-8 under the same conditions but the combination of etanercept and an antibody which binds IL-1b resulted in a 46% decrease in endogenous IL-8 release. The present data indicate that while inhibition of TNFa can enhance adiponectin, it requires blocking the effects of both TNFa and IL-1b to reduce IL-8 release. 35 Thus the primary negative regulator of adiponectin release is likely to be TNFa rather than IL-8 whose release is, in part, secondary to that of TNFa and IL-1b. The finding that insulin also enhanced adiponectin release by omental adipose tissue explants by almost 30% over a 48 h incubation is in agreement with the report by Halleux et al. 36 that insulin enhances adiponectin mRNA accumulation in human omental adipose tissue explants. Thus, the reduced adiponectin release observed by adipose tissue explants from diabetic obese individuals as compared to obese individuals with the same BMI could reflect inhibition of endogenous insulin effects on adiponectin release by human omental adipose tissue.
In conclusion, the present data are compatible with the hypothesis that the reduced release of adiponectin in obesity is secondary to enhanced TNFa release and that the further decrease seen in type 2 diabetes is linked to insulin resistance. Adiponectin mRNA is found in appreciable amounts in the freshly isolated non-fat cell fractions obtained by collagenase digestion of human omental adipose tissue but not in cultured preadipocytes. However, the question of whether there is any contribution of cells other than adipocytes to circulating adiponectin in humans remains to be answered.
